Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of life science diagnostic and research equipment expert Bio-Rad Laboratories
So what: It appears that Bio-Rad's stock is climbing on sad news. It was announced late yesterday that David Schwartz, the company's 88-year-old co-founder and chairman, passed away over the weekend.
While a headline at MarketWatch reads "Bio-Rad jumps 12% on Luminex deal," the extension of a sales and distribution agreement with longtime partner Luminex
Now what: In the hefty book of inadvisable investor moves, one of my least favorites is chasing merger and acquisition rumors. I'm sure the strategy works out on occasion. However, trying to get rich on rumor and speculation is more likely a great way to ruin your retirement -- or whatever else your investment portfolio is aimed at. In this Fool's opinion, chasing Bio-Rad's run today is about as wise as "investing" in lotto tickets.
Want to keep up to date on Bio-Rad Laboratories? Add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
Fool contributor Matt Koppenheffer has nofinancial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter, @KoppTheFool, or on Facebook. The Fool's disclosure policy prefers dividends over a sharp stick in the eye.